Search alternatives:
significant risks » significant risk (Expand Search), significant results (Expand Search), significant role (Expand Search)
risks decrease » sizes decrease (Expand Search), visits decreased (Expand Search), rivers decreased (Expand Search)
point decrease » point increase (Expand Search)
small decrease » small increased (Expand Search)
Showing 1 - 20 results of 5,940 for search '(( significant risks decrease ) OR ( significant ((point decrease) OR (small decrease)) ))', query time: 0.40s Refine Results
  1. 1
    HFD decreases intermediate-term memory.

    HFD decreases intermediate-term memory. by Tong Yue (6033305)

    Published 2025
    “…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. There was no significant decline in the survival rate in flies fed with HFD compared with ND (n = 10 vials, containing 20 flies at each time point). …”
    Save to List
    Saved in:
  2. 2
    Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity.

    Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Patient demographic information at four time points.

    Patient demographic information at four time points. by Ruitian Song (11045127)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Innovation and night light in large and small cities.

    Innovation and night light in large and small cities. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:
  5. 5
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Flow chart of participants selection.

    Flow chart of participants selection. by Linjia Duan (13276989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA.

    Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA. by Rahul H. Jayaram (21463899)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: